ECSP066902A - Soluciones sólidas supersaturadas estabilizadas de drogas esteroides - Google Patents

Soluciones sólidas supersaturadas estabilizadas de drogas esteroides

Info

Publication number
ECSP066902A
ECSP066902A EC2006006902A ECSP066902A ECSP066902A EC SP066902 A ECSP066902 A EC SP066902A EC 2006006902 A EC2006006902 A EC 2006006902A EC SP066902 A ECSP066902 A EC SP066902A EC SP066902 A ECSP066902 A EC SP066902A
Authority
EC
Ecuador
Prior art keywords
supersatured
stabilized
solid solutions
lipophilic
steroid drugs
Prior art date
Application number
EC2006006902A
Other languages
English (en)
Inventor
Ralph Lipp
Adrian Funke
Torsten Wagner
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066902(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of ECSP066902A publication Critical patent/ECSP066902A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a una composición farmacéu-tica con disolución de drogas lipofílicas mejoradas en un medio acuoso. Se comprobó que composiciones farmacéuticas que comprenden un polvo de compuestos lipofílicos tales como hormonas, y esteroides (por ejemplo, drospirenona y valerato de estradiol) en forma dispersa a nivel molecular junto a un vehículo que posee un área superficial específica de al me-nos 250 m2/g, tal como dióxido de silicio, por ejemplo, di-óxido de silicio comercializado bajo la denominación Aero-perl®, posee mejores propiedades de disolución de la droga lipofílica.
EC2006006902A 2004-03-10 2006-10-02 Soluciones sólidas supersaturadas estabilizadas de drogas esteroides ECSP066902A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55133004P 2004-03-10 2004-03-10
EP04075714 2004-03-10

Publications (1)

Publication Number Publication Date
ECSP066902A true ECSP066902A (es) 2006-12-20

Family

ID=34928105

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006902A ECSP066902A (es) 2004-03-10 2006-10-02 Soluciones sólidas supersaturadas estabilizadas de drogas esteroides

Country Status (32)

Country Link
US (1) US8715735B2 (es)
EP (2) EP1765290B1 (es)
JP (1) JP5006185B2 (es)
KR (1) KR101210695B1 (es)
CN (1) CN1984644B (es)
AR (1) AR048500A1 (es)
AT (1) ATE442131T1 (es)
AU (1) AU2005221403B8 (es)
BR (1) BRPI0507342A (es)
CA (1) CA2558582C (es)
CR (1) CR8630A (es)
DE (1) DE602005016551D1 (es)
DK (1) DK1765290T3 (es)
EA (1) EA012746B1 (es)
EC (1) ECSP066902A (es)
ES (2) ES2332229T3 (es)
GT (1) GT200500045A (es)
HR (1) HRP20090614T1 (es)
IL (1) IL177894A0 (es)
MY (1) MY142989A (es)
NO (1) NO20064473L (es)
NZ (1) NZ549793A (es)
PA (1) PA8626101A1 (es)
PE (1) PE20060016A1 (es)
PL (1) PL1765290T3 (es)
PT (1) PT1765290E (es)
RS (1) RS51076B (es)
SI (1) SI1765290T1 (es)
SV (1) SV2005002044A (es)
TW (1) TWI345986B (es)
UY (1) UY28803A1 (es)
WO (1) WO2005087199A2 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
US10016442B2 (en) * 2005-06-16 2018-07-10 Allergan Pharmaceuticals International Limited Estrogen compositions for vaginal administration
EP1898880A2 (en) * 2005-06-16 2008-03-19 Warner Chilcott Company Inc. Gel compositions for topical administration
WO2007128350A1 (en) * 2006-05-10 2007-11-15 Evonik Degussa Gmbh Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
HUE029842T2 (en) 2007-02-23 2017-04-28 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
AU2008239683B2 (en) * 2007-04-11 2014-03-27 Pharmaceuticals Productions Inc Melatonin tablet and methods of preparation and use
AU2009214193A1 (en) * 2008-02-13 2009-08-20 Bayer Intellectual Property Gmbh Estradiol-containing drug delivery system
US8722094B2 (en) * 2008-03-11 2014-05-13 Aska Pharmaceutical Co., Ltd. Solid dispersion and pharmaceutical composition of the same, and production processes thereof
ES2553897T3 (es) 2008-05-02 2015-12-14 Gilead Sciences, Inc. El uso de partículas de vehículo sólido para mejorar la procesabilidad de un agente farmacéutico
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
WO2010042930A1 (en) * 2008-10-10 2010-04-15 Ahmed Salah U Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate
WO2010094623A1 (en) * 2009-02-18 2010-08-26 Bayer Schering Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
CN102413813B (zh) * 2009-03-24 2014-11-12 Adds制药有限责任公司 用于口服递送的稳定化的溶解性增强的制剂
FR2947178B1 (fr) * 2009-06-29 2012-07-06 Effik Composition pharmaceutique a base de progesterone micronisee et ses utilisations
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
US20140178479A1 (en) * 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
LT2782584T (lt) 2011-11-23 2021-09-10 Therapeuticsmd, Inc. Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HK1216240A1 (zh) 2012-11-14 2016-10-28 W. R. Grace & Co.-Conn. 含有生物活性材料与无序无机氧化物的组合物
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20140303128A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2016014454A1 (en) 2014-07-21 2016-01-28 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
CA2951284A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
CN106109420B (zh) * 2016-08-11 2018-07-06 吴启旸 依普利酮固体分散体及其制剂
BR112019016692B1 (pt) * 2017-02-14 2023-12-05 Dsm Ip Assets B.V Formulações estáveis em armazenamento e uso das mesmas
CN110290710B (zh) * 2017-02-14 2023-12-19 帝斯曼知识产权资产管理有限公司 水分散性制剂
CN110013467B (zh) * 2018-01-10 2021-09-17 上海汉都医药科技有限公司 一种固体微粒及其制备方法和含其的药物组合物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
JP2022069437A (ja) * 2020-10-23 2022-05-11 富士製薬工業株式会社 医薬製剤およびその製造方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA72698B (en) 1972-02-03 1973-09-26 Liebenberg R W Method of preparing medicinal compositions
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
GB8403359D0 (en) * 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
IT1216570B (it) * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
DE3916112A1 (de) * 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
CA2050067C (en) 1990-08-30 2000-05-30 Yasushi Morita Controlled drug release composition
EP0492007B1 (en) * 1990-11-29 1995-02-08 F.H. FAULDING & CO. LIMITED Process for producing liquid loaded powders
DE4326240A1 (de) * 1993-08-02 1995-02-09 Schering Ag 15,15-Dialkyl-substituierte Derivate des Estradiols
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
US6027747A (en) 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
KR20000000016A (ko) 1999-02-10 2000-01-15 김일 자동차용번호판부착볼트구조
DE122009000007I2 (de) 1999-08-31 2011-07-21 Bayer Schering Pharma Pharmazeutische kombination von ethinylestradiol und drospirenone als empfangnisverhutendes mittel.
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
NZ520630A (en) 2000-01-18 2004-09-24 Schering Ag Drospirenone for hormone replacement therapy
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
OA12625A (en) * 2001-06-22 2006-06-12 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug.
ITMC20010031U1 (it) 2001-07-05 2003-01-07 Best Raffaello Srl Recipiente di cartone ad uso alimentare, dotato di un tratto anulare superiore asportabile a strappo
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
CA2497838C (en) 2002-09-05 2012-07-17 Pantarhei Bioscience B.V. Pharmaceutical application of 15- or 16- substituted testosterone analogues
ATE454155T1 (de) 2002-11-05 2010-01-15 Bayer Schering Pharma Ag Verwendung von drospirenon zur behandlung von hypertension
DE20217332U1 (de) 2002-11-11 2003-02-27 Brand Factory Swiss Gmbh, Rotkreuz Socke
WO2004073689A1 (en) * 2003-02-19 2004-09-02 Lifecycle Pharma A/S Use of a silica or silica derivative as a sorption material
FR2851918B1 (fr) 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
KR20060130723A (ko) 2004-03-10 2006-12-19 쉐링 악티엔게젤샤프트 분자 분산된 드로스피레논을 포함하는 조성물

Also Published As

Publication number Publication date
IL177894A0 (en) 2006-12-31
CR8630A (es) 2007-06-06
MY142989A (en) 2011-02-14
AU2005221403B2 (en) 2009-12-10
KR20060132999A (ko) 2006-12-22
EA200601588A1 (ru) 2007-02-27
RS51076B (sr) 2010-10-31
ES2332229T3 (es) 2010-01-29
BRPI0507342A (pt) 2007-07-03
TWI345986B (en) 2011-08-01
PT1765290E (pt) 2009-11-23
US8715735B2 (en) 2014-05-06
KR101210695B1 (ko) 2012-12-11
EA012746B1 (ru) 2009-12-30
US20050207990A1 (en) 2005-09-22
SI1765290T1 (sl) 2010-01-29
SV2005002044A (es) 2005-11-04
CA2558582A1 (en) 2005-09-22
ATE442131T1 (de) 2009-09-15
AR048500A1 (es) 2006-05-03
HRP20090614T1 (hr) 2009-12-31
NO20064473L (no) 2006-10-10
WO2005087199A2 (en) 2005-09-22
WO2005087199A8 (en) 2007-03-29
EP1765290A2 (en) 2007-03-28
GT200500045A (es) 2005-10-31
AU2005221403A1 (en) 2005-09-22
PA8626101A1 (es) 2006-07-03
NZ549793A (en) 2010-06-25
CN1984644B (zh) 2010-12-08
EP1765290B1 (en) 2009-09-09
ES2390406T3 (es) 2012-11-12
PL1765290T3 (pl) 2010-02-26
JP5006185B2 (ja) 2012-08-22
JP2007528389A (ja) 2007-10-11
DE602005016551D1 (de) 2009-10-22
EP2087883A1 (en) 2009-08-12
CN1984644A (zh) 2007-06-20
TW200600116A (en) 2006-01-01
AU2005221403B8 (en) 2010-01-07
CA2558582C (en) 2013-07-16
HK1103660A1 (en) 2007-12-28
DK1765290T3 (da) 2009-11-02
EP2087883B1 (en) 2012-07-25
WO2005087199A3 (en) 2009-01-15
PE20060016A1 (es) 2006-02-16
UY28803A1 (es) 2005-10-31

Similar Documents

Publication Publication Date Title
ECSP066902A (es) Soluciones sólidas supersaturadas estabilizadas de drogas esteroides
IL177893A0 (en) Compositions comprising drospirenone molecularly dispersed
MX336930B (es) Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
EA200900572A1 (ru) Мицеллярные наночастицы с химическими субстанциями
SV2011003852A (es) Particulas inhalables que comprenden tiotropio
WO2008061014A3 (en) Self-assembling peptide amphiphiles for tissue engineering
HK1220445A1 (zh) 具有摇溶性以及增强的溶解再现性和稳定性的组合物
PA8853801A1 (es) Composición de liberación pulsátil de sildenafil y proceso para prepararla
CU20060177A7 (es) Soluciones sólidas supersaturadas estabilizadas de drogas esteroides
WO2011130834A8 (en) Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof
Kalava et al. Physicochemical characterization and dissolution properties of cinnarizine solid dispersions
CY1109564T1 (el) Σταθεροποιημενα υπερκορεσμενα στερεα λιποφιλων φαρμακων
WO2011074931A3 (es) Formulación farmacéutica parenteral en suspensión, de liberación sostenida, en dosis baja y ultra baja, en terapia hormonal en el síndrome climatérico
UA87838C2 (ru) Стабилизированные перенасыщенные твердые растворы липофильных лекарствнных средств
TW200609000A (en) Molecular dispersions of drospirenone
TH98589B (th) องค์ประกอบทางเภสัชกรรมที่มีเททระไฮโดรโฟลิคแอซิด
TH98589A (th) องค์ประกอบทางเภสัชกรรมที่มีเททระไฮโดรโฟลิคแอซิด